Baxter International Inc. - Q1 2002 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2002. Baxter International Inc. operates in three primary segments: Medication Delivery, BioScience, and Renal. The company is headquartered in Deerfield, Illinois. As of April 25, 2002, there were 601,093,841 shares of common stock outstanding.
Key Financial Metrics
| Metric (in millions) | Q1 2002 | Q1 2001 |
|---|---|---|
| Net Sales | $1,950 | $1,757 |
| Net Income | $253 | $162 |
| Diluted EPS | $0.41 | $0.27 |
| Gross Margin | 45.4% | 43.9% |
| Cash Flow from Operations | ($100) | ($33) |
| Capital Expenditures | ($139) | ($131) |
| Total Debt (Short + Long Term) | $3,219 | N/A |
| Cash and Equivalents | $522 | $723 |
Note: Q1 2001 Net Income included a $52 million cumulative effect of an accounting change (SFAS 133). Q1 2002 reflects the adoption of SFAS 142, eliminating goodwill amortization.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11% year-over-year. Excluding currency fluctuations, sales grew 14%.
- Profitability: Net income rose 56% to $253 million. Diluted EPS increased 17% to $0.41 (excluding the 2001 accounting change impact).
- Segment Performance:
- BioScience: Sales up 18% (21% constant currency); Pretax income up 51%.
- Medication Delivery: Sales up 10% (12% constant currency); Pretax income up 18%.
- Renal: Sales up 2% (7% constant currency); Pretax income down 15% due to currency impacts and R&D spending.
- Cash Flow: Operating cash flow was negative $100 million, driven by increases in accounts receivable and inventories, despite higher earnings.
- Accounting Changes: Goodwill amortization ceased effective Jan 1, 2002, under SFAS 142. Goodwill is now subject to impairment testing.
Guidance, Outlook, and Risks
- Outlook: Management expects to accelerate sales growth to the low-teens and grow EPS in the mid-teens for the full year 2002. R&D spending is expected to increase significantly in the remainder of the year.
- Acquisitions: The company agreed to acquire Fusion Medical Technologies, Inc. (expected to close Q2 2002) to expand biosurgery capabilities. It also acquired Autros Healthcare Solutions in January 2002.
- Liquidity: The company issued $500 million in term debt in April 2002. The net-debt-to-capital ratio was 40.6% at March 31, 2002.
- Risks and Contingencies:
- Legal Proceedings: Significant litigation remains regarding mammary implants (231 lawsuits pending), plasma-based therapies (HIV/Hepatitis C claims), and dialyzer safety. Management believes reserves are adequate but future charges could impact net income.
- Currency: A strengthening U.S. dollar negatively impacted reported sales growth.
- Regulatory: Investigations into Medicare/Medicaid drug pricing practices are ongoing.
Investor Verification Checklist
- Verify the impact of the pending Fusion Medical Technologies acquisition on future BioScience segment margins.
- Monitor the status of mammary implant and plasma-based therapy litigation for potential reserve adjustments.
- Assess the sustainability of the negative operating cash flow trend given the buildup in receivables and inventory.
- Review the progress of the goodwill impairment review required under SFAS 142.
- Track the outcome of government investigations into drug pricing practices.